Back to top

cell-therapy: Archive

Zacks Equity Research

Agilent (A) Boosts DCG Segment With New ProteoAnalyzer System

Agilent (A) unveils its new ProteoAnalyzer system in a bid to strengthen its Diagnostics and Genomics Group segment.

APositive Net Change INCYPositive Net Change ANETPositive Net Change PYPLPositive Net Change

Zacks Equity Research

Legend Biotech (LEGN) Up 12% on Reports of Takeover Bid

A third-party article suggests that Legend Biotech (LEGN) hired investment banking firm Centerview Partners to help its board review the takeover offer.

BMYPositive Net Change JNJPositive Net Change LEGNNegative Net Change TSVTPositive Net Change

Zacks Equity Research

Cartesian (RNAC) MG Study Meets Goals, Stock Down on Other Updates

Cartesian (RNAC) announced that the phase IIb study in MG patients has achieved its primary endpoints. However, the stock nosedives following an equity financing announcement.

NERVNegative Net Change ARGXPositive Net Change ALXONegative Net Change RNACPositive Net Change

Zacks Equity Research

Mesoblast (MESO) Soars 208% YTD on Positive Regulatory Updates

Mesoblast (MESO) skyrockets 208.2% year to date on encouraging progress with its pipeline candidates.

NVSPositive Net Change INCYPositive Net Change MESONegative Net Change ALXONegative Net Change

Zacks Equity Research

Mustang (MBIO) Soars 477% on Data From Rare Blood Cancer Study

Updated data from a clinical study shows that treatment with Mustang Bio's (MBIO) experimental cell therapy achieved an overall response rate of 90% in patients with a rare form of blood cancer.

JNJPositive Net Change ABBVPositive Net Change BGNENegative Net Change MBIOPositive Net Change